19 completed, 12 unknown, 11 recruiting. 16 Phase 4, 7 Phase 1, 6 Not applicable, 6 Phase 2, 5 Phase 3.
Follow Empagliflozin 25 MG: new trials by email Literature Review of Empagliflozin 25 MG trials Research Report on Empagliflozin 25 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGLT2i, Pioglitazone, and Ketone Production in T2D Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d) - Type 2 Diabetes | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 64 | 2026-05-11 | 2026-07-17 |
| SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia Empagliflozin 25 MG - Type 2 Diabetes | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 29 | 2025-04-29 | 2026-07-17 |
| SGLT2i, Hepatic Glucose Production, and SNS Empagliflozin 25 MG - Type 2 Diabetes | Early Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 22 | 2025-01-07 | 2026-07-17 |
| meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis Empagliflozin 25 MG - Peritoneal Dialysis Complication, End Stage Kidney Disease | Phase 3 | Recruiting | University Health Network, Toronto | 20 | 2024-09-01 | 2026-05-01 |
| To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults Empagliflozin 25 MG, Ezetimibe/Rosuvastatin 10/10mg, Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg - Type 2 Diabetes, Dyslipidemias | Phase 1 | Unknown | Hyundai Pharm | 56 | 2024-06-20 | 2024-08-29 |
| Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease Empagliflozin 25 MG, Placebo - Heart Failure with Reduced Ejection Fraction, End Stage Renal Disease on Dialysis | Phase 4 | Recruiting | National Taiwan University Hospital | 95 | 2024-03-13 | 2024-12-13 |
| EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease Empagliflozin 25 MG, Placebo - Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis | Phase 4 | Recruiting | National Taiwan University Hospital | 150 | 2024-03-05 | 2024-12-16 |
| Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia Empagliflozin 25 MG, Sitagliptin 100mg - Type 2 Diabetes | Not applicable | Completed | Medanta, The Medicity, India | 220 | 2024-01-01 | 2025-06-13 |
| Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus Empagliflozin 25 MG, Linagliptin 5 mg Oral Tablet - Diabetes Mellitus, Kidney Transplant; Complications | Not applicable | Unknown | Medanta, The Medicity, India | 200 | 2023-11-10 | 2023-10-24 |
| Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus Empagliflozin 25 MG, Linagliptin - Kidney Transplant; Complications, Diabetes Mellitus | Not applicable | Recruiting | Medanta, The Medicity, India | 200 | 2023-10-30 | 2024-12-05 |
| SGLTi, Hepatic Glucose Production and Ketogenesis Empagliflozin 25 MG, Placebo - Type 2 Diabetes | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 30 | 2023-10-05 | 2026-07-17 |
| The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Empagliflozin 25 MG, Placebo - Obesity, Metabolic Syndrome | Phase 1 / Phase 2 | Recruiting | Vanderbilt University Medical Center | 74 | 2023-09-06 | 2026-09-01 |
| Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease Empagliflozin 25 MG, Enalapril Maleate 20 mg - Diabetic Nephropathy Type 2 | Phase 2 / Phase 3 | Unknown | Omar Tarek Elfarargi | 212 | 2023-03-01 | 2022-05-13 |
| Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes Pioglitazone 45 mg, Empagliflozin 25 MG, Semaglutide 7 MG - Type 2 Diabetes | Not applicable | Recruiting | Karolinska Institutet | 60 | 2023-02-08 | 2025-02-26 |
| Empagliflozin in Acute Heart Failure Empagliflozin 25 MG - Acute Heart Failure, Chronic Kidney Diseases | Phase 4 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 25 | 2022-12-22 | 2026-03-16 |
| Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy Empagliflozin 25 mg, Placebo - Epilepsy | Early Phase 1 | Unknown | Washington University School of Medicine | 18 | 2022-08-17 | 2022-08-23 |
| Empagliflozin in Treatment of Peripheral Diabetic Neuropathy Empagliflozin 25 MG - Diabetic Neuropathy Peripheral | Phase 1 / Phase 2 | Completed | Tanta University | 50 | 2022-01-20 | 2023-11-24 |
| Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation Empagliflozin 25 MG, Insulin - Kidney Transplant; Complications | Not applicable | Completed | Shahid Beheshti University of Medical Sciences | 40 | 2022-01-01 | 2025-09-08 |
| Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome Empagliflozin 25 mg, Linagliptin 10 mg, Metformin 1500 mg - Polycystic Ovary Syndrome (PCOS) | Phase 4 | Unknown | Alexandria University | 75 | 2021-12-07 | 2022-01-21 |
| Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass Empagliflozin 25 MG, Placebo - Dumping Syndrome, Hypoglycemia, Reactive | Phase 4 | Completed | Insel Gruppe AG, University Hospital Bern | 22 | 2021-12-01 | 2023-03-14 |
Showing 20 of 42. Sign in to see all of them.
Diabetes Mellitus, Type 2 (15) · Diabetes Mellitus (7) · Kidney Failure, Chronic (3) · Acute Kidney Injury (2) · Coronary Artery Disease (2) · Obesity (2) · Renal Insufficiency, Chronic (2) · Arrhythmias, Cardiac (1) · Coronary Disease (1) · Diabetic Nephropathies (1) · Diabetic Retinopathy (1) · Dumping Syndrome (1) · Dyslipidemias (1) · Epilepsy (1) · Glomerulonephritis (1)
The University of Texas Health Science Center at San Antonio (6) · Medanta, The Medicity, India (3) · Boehringer Ingelheim (2) · Insel Gruppe AG, University Hospital Bern (2) · National Taiwan University Hospital (2) · University of Sao Paulo General Hospital (2) · Vanderbilt University Medical Center (2) · Alexandria University (1) · Amsterdam UMC, location VUmc (1) · Asmaa Abdelfattah Elsayed (1) · Centro Universitario de Ciencias de la Salud, Mexico (1) · Christian Schulze (1) · Chungbuk National University Hospital (1) · Fayoum University (1) · Hyundai Pharm (1)
United States (10) · Egypt (4) · Brazil (3) · Switzerland (3) · Canada (2) · Denmark (2) · Germany (2) · India (2) · Iran (2) · Japan (2) · Netherlands (2) · Taiwan (2) · Malaysia (1) · Mexico (1) · South Korea (1)
Ralph DeFronzo, MD (4) · Chih-Cheng Wu, MD. PhD (2) · Ahmed I ElMallah, PhD (1) · Asmaa A Elsayed, PhD (1) · Bruno Caramelli, MD, PhD (1) · Carlos V Serrano, MD (1) · Carlos V Serrano, MD, PhD (1) · Carolina Solis-Herrera, MD (1) · Christian Schulze, Prof. Dr. (1) · Daniel Fuster, MD (1) · Donna SH Lin, MD (1) · Donna Shu-Han Lin, MD (1) · Eu Jeong Ku, MD, PhD (1) · Eugene J Barrett, MD PhD (1)
PMID 15882287, PMID 24279801, PMID 24344941, PMID 25307034, PMID 28533501, PMID 30862658, PMID 31539565, PMID 40855136, PMID 11588337, PMID 11794168, PMID 11889147, PMID 12105309, PMID 19429873, PMID 22223765, PMID 27964837, PMID 30091172, PMID 30912033, PMID 33915345, PMID 35288397, PMID 35322793, PMID 35766022, PMID 36123073, PMID 37093196, PMID 37365618, PMID 37369826, PMID 37380728, PMID 37703527, PMID 38653618, PMID 38770818, PMID 39747681, PMID 39963952, PMID 9527963
R01DK024092 (4), 2019 (1), R01DK097554 (1), R01HL142250 (1)